molmed

Governance

Report on corporate governance and ownership structure 2018 (in Italian) ▾

Report on corporate governance and ownership structure 2018 (in Italian)

Governance

Annual remuneration report 2017 (in Italian) ▾

Annual remuneration report 2017 (in Italian)

Investors

MolMed announces the decision to suspend the enrollment of new patients in phase III study TK008 with Zalmoxis®.

MolMed announces the decision to suspend the enrollment of new patients in phase III study TK008 with Zalmoxis®. ▾

Governance

Annual remuneration report 2019 (in Italian) ▾

Annual remuneration report 2019 (in Italian)

News & Events

Stay update

24 September MOLMED OPEN DOORS in the EUROPEAN BIOTECH WEEK 2019 ▾

24 September MOLMED OPEN DOORS in the EUROPEAN BIOTECH WEEK 2019

The European Biotech Week 2019 will be celebrate across Europe between 23th to 29th September, encouraging the general public to explore the fascinating, vibrant world of biotechnology, which is a key part of our lives.

Guided tour of the GMP facility labs and of the quality control and development labs.

24th September from 10:00 AM til 12:00

To partecipate: info@molmed.com

ARM Cell & Gene Meeting on the MESA

Read more about ARM Cell & Gene Meeting on the MESA

http://www.meetingonthemesa.com/

Carlsbad California

News & Events

Stay update

PHACILITATE LEADERS EU ▾

PHACILITATE LEADERS EU

Advocating Europe Excellence in Advanced Therapies

https://www.phacilitate-leaders-europe.com/

Royal Lancaster London

News & Events

Stay update

ADVANCED TALKS ON ADVANCED THERAPIES ▾

ADVANCED TALKS ON ADVANCED THERAPIES

Il futuro delle terapie avanzate in medicina. Roma - Auditorium Ara Pacis

Investors

The European Patent Office issued the decision to grant to Molmed a new patent on CAR technology.

The European Patent Office issued the decision to grant to Molmed a new patent on CAR technology. ▾

Investors

Results of the independent study INGRID on NGR-hTNF potential in brain lymphomas published by Blood

Results of the independent study INGRID on NGR-hTNF potential in brain lymphomas published by Blood ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.